WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia
February 27, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 27, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide...
WPD Pharmaceuticals Granted Key Patent Exclusively Licensed From Wake Forest University
February 24, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia , Feb. 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial
February 20, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide...
WPD Pharmaceuticals’ WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials
February 18, 2020 07:35 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, in collaboration...
WPD Pharmaceuticals to Conduct Clinical Trials in Pediatric Brain Tumors Through Collaboration With CNS Pharmaceuticals
February 12, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery
February 10, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 10, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation
February 05, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 05, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Completed the Acquisition of Two Drug Candidates Bringing Total Development Funding Spent on Drugs Under License to Over USD $100 Million
February 03, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 03, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, provides an update...
WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates
January 31, 2020 16:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 31, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, provides this update...
WPD Pharmaceuticals Receives European Patent for Cancer Targeting Drugs
January 29, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 29, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1)(“WPD” or the “Company”) a clinical stage pharmaceutical company, is pleased to announce...